These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 27197548)

  • 21. Reversibility of neuropathology in Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Ziegler R; Cheng SH; Cox TM
    Hum Mol Genet; 2014 Feb; 23(3):730-48. PubMed ID: 24057669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
    Norflus F; Yamanaka S; Proia RL
    DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.
    Walia JS; Altaleb N; Bello A; Kruck C; LaFave MC; Varshney GK; Burgess SM; Chowdhury B; Hurlbut D; Hemming R; Kobinger GP; Triggs-Raine B
    Mol Ther; 2015 Mar; 23(3):414-22. PubMed ID: 25515709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma G
    Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
    Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosis.
    Ornaghi F; Sala D; Tedeschi F; Maffia MC; Bazzucchi M; Morena F; Valsecchi M; Aureli M; Martino S; Gritti A
    Neurobiol Dis; 2020 Feb; 134():104667. PubMed ID: 31682993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/nCas9-Based Genome Editing on GM2 Gangliosidoses Fibroblasts via Non-Viral Vectors.
    Leal AF; Cifuentes J; Quezada V; Benincore-Flórez E; Cruz JC; Reyes LH; Espejo-Mojica AJ; Alméciga-Díaz CJ
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
    Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
    Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of motor and behavioral activity in Sandhoff mice transplanted with human CD34+ cells transduced with a HexA/HexB expressing lentiviral vector.
    Beegle J; Hendrix K; Maciel H; Nolta JA; Anderson JS
    J Gene Med; 2020 Sep; 22(9):e3205. PubMed ID: 32335981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice.
    Guidotti JE; Mignon A; Haase G; Caillaud C; McDonell N; Kahn A; Poenaru L
    Hum Mol Genet; 1999 May; 8(5):831-8. PubMed ID: 10196372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of inducible models of Tay-Sachs and related disease.
    Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
    PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased phosphorylation of HexM improves lysosomal uptake and potential for managing GM2 gangliosidoses.
    Benzie G; Bouma K; Battellino T; Cooper S; Hemming R; Kammouni W; Liu L; Do C; Khajehpour M; Perreault H; Kornfeld S; Triggs-Raine B; Mark BL
    BBA Adv; 2022; 2():100032. PubMed ID: 37082581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.
    Liu Y; Hoffmann A; Grinberg A; Westphal H; McDonald MP; Miller KM; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8138-43. PubMed ID: 9223328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.
    Kitakaze K; Tasaki C; Tajima Y; Hirokawa T; Tsuji D; Sakuraba H; Itoh K
    Biochem Biophys Rep; 2016 Sep; 7():157-163. PubMed ID: 28955902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
    Seyrantepe V; Demir SA; Timur ZK; Von Gerichten J; Marsching C; Erdemli E; Oztas E; Takahashi K; Yamaguchi K; Ates N; Dönmez Demir B; Dalkara T; Erich K; Hopf C; Sandhoff R; Miyagi T
    Exp Neurol; 2018 Jan; 299(Pt A):26-41. PubMed ID: 28974375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pathogenic HEXA missense variant in wild boars with Tay-Sachs disease.
    Bertani V; Prioni S; Di Lecce R; Gazza F; Ragionieri L; Merialdi G; Bonilauri P; Jagannathan V; Grassi S; Cabitta L; Paoli A; Morrone A; Sonnino S; Drögemüller C; Cantoni AM
    Mol Genet Metab; 2021 Jul; 133(3):297-306. PubMed ID: 34119419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic correction in microglia derived from Sandhoff disease model mice.
    Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
    J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.
    Akeboshi H; Chiba Y; Kasahara Y; Takashiba M; Takaoka Y; Ohsawa M; Tajima Y; Kawashima I; Tsuji D; Itoh K; Sakuraba H; Jigami Y
    Appl Environ Microbiol; 2007 Aug; 73(15):4805-12. PubMed ID: 17557860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer.
    Akli S; Guidotti JE; Vigne E; Perricaudet M; Sandhoff K; Kahn A; Poenaru L
    Gene Ther; 1996 Sep; 3(9):769-74. PubMed ID: 8875224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.
    Rockwell HE; McCurdy VJ; Eaton SC; Wilson DU; Johnson AK; Randle AN; Bradbury AM; Gray-Edwards HL; Baker HJ; Hudson JA; Cox NR; Sena-Esteves M; Seyfried TN; Martin DR
    ASN Neuro; 2015; 7(2):. PubMed ID: 25873306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.